Clinical trials: System; Sclerosis
Multiple Sclerosis
Natalizumab and Chronic Inflammation
In this study the investigators will assess the ability of Natalizumab, a medication given to treat multiple sclerosis (MS), to restore blood brain barrier integrity and repair subtle leakages of the blood brain barrier (BBB).
- Trial name
- NCT05177718
- Testing
- Natalizumab 300 MG in 15 ML Injection
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Vanderbilt University Medical Center
Inherited Mitochondrial Disease
A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease
The primary objective of this study is to assess the safety of vatiquinone in participants with inherited mitochondrial disease who had prior exposure to vatiquinone in a PTC/BioElectron sponsored (previously Edison) clinical…
- Trial name
- NCT05218655
- Testing
- Vatiquinone
- Where
- 26 sites in United States, France and 5 more
- Volunteers
- 101 people
- Sponsor
- PTC Therapeutics
Amyotrophic Lateral Sclerosis
Gilenya in Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to determine whether Gilenya, also known as fingolimod, is safe and tolerable in patients with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT01786174
- Testing
- Gilenya
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Interstitial Lung Disease, Connective Tissue Disease
A Clinical Trial for CTD-ILD Treatment
The first objective of this protocol is to assess the tolerability and safety of N-acetylcysteine (NAC) in patients with connective tissue disease related interstitial lung disease (CTD-ILD).
- Trial name
- NCT01424033
- Testing
- N-Acetylcysteine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Michigan
Pulmonary Arterial Hypertension, Systemic Sclerosis
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
This will be a 36-week, single group, open label study assessing the effects of Tadalafil plus Ambrisentan combination therapy in patients with pulmonary arterial hypertension associated with the scleroderma spectrum of disease…
- Conditions
- Pulmonary Arterial Hypertension, Systemic Sclerosis, Scleroderma Spectrum of Diseases, Connective Tissue Disease
- Trial name
- ATPAHSS (NCT01042158)
- Testing
- tadalafil and ambrisentan upfront combination therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Johns Hopkins University
Tuberous Sclerosis Complex
Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)
Tuberous Sclerosis Complex (TSC) is a multi-system disease, usually presenting with seizures, mental retardation and autism, and exhibiting a high variability in clinical findings both among and within families.
- Trial name
- TSC (NCT01289912)
- Testing
- RAD001
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- Mustafa Sahin
Relapsing-Remitting Multiple Sclerosis
Safety and Tolerability of Glatiramer Acetate
This is an open-label, randomized, multi-center, parallel-arm study to assess the safety and tolerability of a daily dose of Glatiramer Acetate (GA) 40 mg/mL three times a week (TIW) administered subcutaneously (SC) as compared…
- Trial name
- GLACIER (NCT01874145)
- Testing
- GA 20 mg/mL, GA 40 mg/mL
- Where
- 35 sites in United States
- Volunteers
- 209 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis
Isokinetic Exercises in Patients With Multiple Sclerosis
The investigators evaluated the effects of isokinetic muscle strengthening exercises of the quadriceps and hamstring on muscle strength, joint position sense, pain, kinesiophobia and quality of life in patients with multiple…
- Trial name
- NCT03779724
- Testing
- exercises
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Aksaray University Training and Research Hospital
Systemic Sclerosis, Pulmonary; Hypertension
Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
A double-blinded, placebo-controlled study of Dimethyl fumarate (DMF) in 34 Systemic Sclerosis-Pulmonary Hypertension (SSc-PAH) patients.
- Trial name
- NCT02981082
- Testing
- Dimethyl Fumarate (DMF)
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Robert Lafyatis
Gastroesophageal Reflux Disease, Systemic Sclerosis
Gastroesophageal Reflux Treatment in Scleroderma
The investigators purposes are to define the prevalence of omeprazole resistance gastroesophageal reflux disease (GERD) in systemic sclerosis (SSc), to compare the efficacy of omeprazole in combination with algycon versus…
- Conditions
- Gastroesophageal Reflux Disease, Systemic Sclerosis, Scleroderma
- Trial name
- GERD-SSc (NCT01878526)
- Testing
- Alginic acid, Domperidone
- Where
- Thailand
- Volunteers
- 80 people
- Sponsor
- Khon Kaen University
Relapsing-Remitting Multiple Sclerosis
Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)
The main purpose of this study was to investigate the effectiveness of cladribine tablets in a UK real-world setting.
- Trial name
- NCT04997148
- Where
- 8 sites in United Kingdom
- Volunteers
- 116 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Optic Neuritis
Ampyra for Optic Neuritis in Multiple Sclerosis
Fifty subjects will be enrolled in this Phase II, investigator-initiated, randomized and blinded cross-over trial of dalfampridine of 8 weeks duration The study will test the hypothesis that dalfampridine, when administered to…
- Trial name
- NCT01337986
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Washington University School of Medicine
Relapsing-Remitting Multiple Sclerosis
An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis
The primary objective of the study is to assess the immunogenicity of Daclizumab High Yield Process (DAC HYP) 150 mg administered every 4 weeks by subcutaneous (SC) injection using the pre-filled syringe (PFS) in participants…
- Trial name
- OBSERVE (NCT01462318)
- Testing
- Midazolam, Caffeine, S-warfarin
- Where
- 19 sites in United States, Czechia and 2 more
- Volunteers
- 133 people
- Sponsor
- Biogen
Multiple Sclerosis, Encephalitis
tDCS and Cognition in Adults With Multiple Sclerosis or Encephalitis
This research is being done to determine whether transcranial direct current stimulation (tDCS) can improve certain mental abilities in individuals with multiple sclerosis (MS) or encephalitis.
- Trial name
- NCT02538094
- Testing
- Anodal Transcranial direct current stimulation
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Johns Hopkins University
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Effect of Noninvasive Ventilation on Lung Function in Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS), or "Lou Gehrig's Disease", is a fatal disorder that causes progressive degeneration and weakening of the muscles of breathing, leading to breathing insufficiency and eventually breathing…
- Trial name
- NCT00537446
- Testing
- noninvasive positive pressure ventilation
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Columbia University
Multiple Sclerosis
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
Ofatumumab is a novel Immunoglobulin 1ĸ ( IgG1ĸ) lytic monoclonal antibody (mAb) that specifically binds to the human Cluster of Differentiation 20 (CD20) antigen of which expression is restricted to B lymphocytes from the pre-B…
- Trial name
- MIRROR (NCT01457924)
- Testing
- Ofatumumab 3mg, Ofatumumab 30mg, Ofatumumab 60mg
- Where
- 61 sites in United States, Bulgaria and 9 more
- Volunteers
- 232 people
- Sponsor
- GlaxoSmithKline
Epilepsy, Tuberous Sclerosis Complex
A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD
The purpose of this study is to measure if the drug called Everolimus effects mTOR signaling (an electrical activity signal in the brain) in patients with Tuberous Sclerosis Complex (TSC) and Focal Cortical Dysplasia (FCD) with…
- Conditions
- Epilepsy, Tuberous Sclerosis Complex, Focal Cortical Dysplasia
- Trial name
- NCT02451696
- Testing
- Everolimus
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- NYU Langone Health
Relapsing Remitting Multiple Sclerosis
ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis
Phase 1 study to assess the safety and biological activity of ATX-MS-1467 in patients with relapsing forms of multiple sclerosis.
- Trial name
- NCT01097668
- Testing
- ATX-MS-1467
- Where
- 16 sites in Russia, United Kingdom
- Volunteers
- 43 people
- Sponsor
- Apitope Technology (Bristol) Ltd.
Multiple Sclerosis
Examining a Wheelchair Exercise-training Intervention for Persons With Multiple Sclerosis
The goal of this randomized controlled clinical trial is to examine the feasibility and initial efficacy of undertaking and delivering a novel, stakeholder-informed exercise training program for wheelchair users with multiple…
- Trial name
- NCT05888727
- Testing
- Seated Physical activity INtervention for persons with MS, "SPIN" program- Intervention Condition, WEllness for Longevity Living with MS (WELL)- Control Condition
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- The University of Texas Health Science Center, Houston
Multiple Sclerosis
Study of Induction Therapy With Mitoxantrone and Plasmapheresis to Treat Aggressive Multiple Sclerosis
The purpose of this study is to compare the effect of combinative induction therapy with mitoxantrone and plasmapheresis versus induction therapy with mitoxantrone alone in cases of aggressive multiple sclerosis
- Trial name
- IMPAMS (NCT01214317)
- Testing
- plasmapheresis
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Isfahan University of Medical Sciences